Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.
Funayama E, Hosonuma M, Tajima K, Isobe J, Baba Y, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Maruyama Y, Sasaki A, Amari Y, Yamazaki Y, Nakashima R, Uchiyama J, Nakano R, Shida M, Sasaki A, Udaka Y, Oguchi T, Sambe T, Kobayashi S, Tsuji M, Kiuchi Y, Kim YG, Wada S, Tsunoda T, Akiyama M, Nobe K, Kuramasu A, Yoshimura K. Funayama E, et al. Among authors: kuramasu a. Biomed Pharmacother. 2024 Dec 23;182:117749. doi: 10.1016/j.biopha.2024.117749. Online ahead of print. Biomed Pharmacother. 2024. PMID: 39719740
MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells.
Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, Maruyama Y, Sasaki A, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Kobayashi S, Horiike A, Hida N, Sambe T, Nobe K, Wada S, Kobayashi H, Tsuji M, Kobayashi S, Tsunoda T, Kudo Y, Kiuchi Y, Yoshimura K. Toyoda H, et al. Among authors: kuramasu a. Sci Rep. 2024 Oct 8;14(1):23401. doi: 10.1038/s41598-024-73712-1. Sci Rep. 2024. PMID: 39379424 Free PMC article.
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Murayama M, et al. Among authors: kuramasu a. Sci Rep. 2024 May 17;14(1):11325. doi: 10.1038/s41598-024-59677-1. Sci Rep. 2024. PMID: 38760458 Free PMC article.
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.
Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, Yamashita T, Motegi K, Saito A, Kohmoto M, Hosonuma M, Kuramasu A, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Horiike A, Goto S, Murakami M, Kim YG, Tsunoda T, Yoshimura K. Otsuka K, et al. Among authors: kuramasu a. Cancer Immunol Immunother. 2024 Jan 27;73(2):23. doi: 10.1007/s00262-023-03608-y. Cancer Immunol Immunother. 2024. PMID: 38280026 Free PMC article.
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K. Hosonuma M, et al. Among authors: kuramasu a. Cancer Sci. 2024 Mar;115(3):752-762. doi: 10.1111/cas.16061. Epub 2024 Jan 22. Cancer Sci. 2024. PMID: 38254257 Free PMC article.
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Hamada K, et al. Among authors: kuramasu a. Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724. eCollection 2023. Front Immunol. 2023. PMID: 37207204 Free PMC article.
Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy.
Honma O, Watanabe C, Fukuchimoto H, Kashiwazaki J, Tateba M, Wagatsuma S, Ogata K, Maki K, Sonou H, Shiga K, Otsuka E, Hiruta M, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Kuramasu A, Kin M, Kubota Y, Sambe T, Horiike A, Ishida H, Shimada K, Umeda M, Tsunoda T, Yoshimura K. Honma O, et al. Among authors: kuramasu a. Front Pharmacol. 2022 Feb 9;13:744916. doi: 10.3389/fphar.2022.744916. eCollection 2022. Front Pharmacol. 2022. PMID: 35222016 Free PMC article.
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsukuma S, Ishiguro T, Sambe T, Horiike A, Kuramasu A, Wada S, Tsurutani J, Inoue E, Uchida N, Kiuchi Y, Kobayashi S, Hoffman RM, Tsunoda T. Hamada K, et al. Among authors: kuramasu a. Anticancer Res. 2021 Oct;41(10):4985-4993. doi: 10.21873/anticanres.15312. Anticancer Res. 2021. PMID: 34593446
57 results